Latest Ratios: P/E Ratio 10.6x · EV/EBITDA N/A · ROE 16.5%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $459M | $397M | $329M | $260M | $255M | $729M | $126M | — |
| Enterprise Value | $431M | $369M | $320M | $256M | $232M | $727M | $115M | — |
| P/E Ratio → | 10.60 | 9.62 | — | — | — | — | — | — |
| P/S Ratio | 2.33 | 2.01 | 1.32 | 1.15 | 1.75 | 14.43 | 5.37 | — |
| P/B Ratio | 1.57 | 1.42 | 1.48 | 1.11 | 0.93 | 2.50 | 11.35 | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.87 | 1.29 | 1.14 | 1.59 | 14.39 | 4.93 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 20.9% | 20.9% | 23.7% | 18.7% | 15.2% | 20.8% | 9.9% | 15.1% |
| Operating Margin | -11.3% | -11.3% | -13.6% | -30.3% | -36.6% | -47.7% | -44.2% | -37.0% |
| Net Profit Margin | 21.0% | 21.0% | -11.0% | -24.9% | -18.7% | -79.3% | -43.4% | -34.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | 16.5% | 16.5% | -12.0% | -22.0% | -9.6% | -26.5% | -126.4% | -216.8% |
| ROA | 14.2% | 14.2% | -9.9% | -18.1% | -8.2% | -22.7% | -6.9% | -3.9% |
| ROIC | -7.2% | -7.2% | -11.5% | -21.2% | -14.8% | -12.4% | -313.2% | — |
| ROCE | -8.3% | -8.3% | -13.8% | -24.4% | -17.2% | -14.4% | -7.2% | -4.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.04 | 0.10 | 0.07 | 0.00 | 0.17 | 0.09 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.04 | -0.01 | -0.08 | -0.01 | -0.93 | -0.17 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -10359.00 | — |
Net cash position: cash ($31M) exceeds total debt ($3M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.38 | 6.38 | 7.07 | 5.81 | 8.20 | 23.07 | 2.27 | 3.85 |
| Quick Ratio | 6.38 | 6.38 | 7.07 | 5.81 | 8.20 | 23.03 | 2.19 | 3.85 |
| Cash Ratio | 3.09 | 3.09 | 5.59 | 4.68 | 7.22 | 22.06 | 1.92 | 747.54 |
| Asset Turnover | — | 0.61 | 0.97 | 0.76 | 0.45 | 0.15 | 1.32 | 0.11 |
| Inventory Turnover | — | — | — | — | — | 73.14 | 41.22 | — |
| Days Sales Outstanding | — | 73.98 | 31.69 | 34.05 | 27.17 | 40.08 | 17.01 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.4% | 10.4% | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $82M | $77M | $74M | $71M | $70M | $13M | $7M |
Persistent Operating Cash Burn
According to recent market data, SRTA trades at a P/S ratio of 2.33, which appears disconnected from its negative operating margins and suggests that investors are pricing in a successful turnaround rather than the current reality of a contracting, loss-making medical logistics business model.
The current P/E of 10.60 is misleading, as it likely reflects non-recurring gains rather than sustainable earnings power. Investors should monitor whether the market continues to value the firm as a high-growth logistics platform or if a re-rating toward a distressed services provider is imminent.
As reported in financial statements, SRTA's gross margin has fluctuated around 21%, yet the company consistently reports negative operating margins, indicating that the core business model is currently unable to cover its administrative and technology overhead without relying on one-time accounting adjustments to reach profitability.
The disconnect between the 20.97% net margin and the -11.34% operating margin warrants deep skepticism regarding the quality of earnings. Until the company demonstrates a path to positive operating margins through mission density, the current profitability profile remains fundamentally strained.
Based on historical data, SRTA has struggled to generate positive returns on invested capital, with ROIC remaining negative for the majority of the last ten quarters, reflecting the difficulty of compounding value while the company undergoes a costly strategic pivot away from its legacy passenger operations.
The negative ROIC trend suggests that the capital deployed into the new medical logistics framework is not yet yielding sufficient returns to justify the investment. Investors should look for a sustained improvement in asset turnover as a primary indicator that the new business model is gaining traction.
As evidenced by the provided financial data, SRTA's DSO has shown significant volatility, peaking at 157 days in 2025Q4, which suggests that the company faces substantial challenges in collecting payments from hospital systems while simultaneously managing its obligations to third-party aircraft and ground transport operators.
The lack of a stable cash conversion cycle indicates that the company's logistics platform is not yet operating with the efficiency required for a high-volume medical service. This friction in working capital management likely exacerbates the company's reliance on its cash reserves to fund daily operations.
Based on industry standards, the P/E ratio is the most commonly misapplied metric for SRTA, as it obscures the company's underlying operating losses and reliance on non-recurring gains, failing to capture the true cash-burn risk inherent in its current asset-light medical logistics business model.
Analysts should instead focus on EV/Sales or mission-based unit economics to evaluate the company's progress. Using P/E in this context provides a false sense of security that ignores the structural challenges of scaling a specialized healthcare logistics platform.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SRTA stock.
Strata Critical Medical, Inc.'s current P/E ratio is 10.6x. The historical average is 9.6x. This places it at the 100th percentile of its historical range.
Strata Critical Medical, Inc.'s return on equity (ROE) is 16.5%. The historical average is -56.7%.
Based on historical data, Strata Critical Medical, Inc. is trading at a P/E of 10.6x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Strata Critical Medical, Inc. has 20.9% gross margin and -11.3% operating margin.